APAF1 and ovarian carcinoma: Inhibition of miR-23a-3p in ovarian cancer increased APAF1 protein levels and enhanced the sensitivity of tumor cells to platinum drugs, whereas overexpression of miR-23a-3p led to decreased APAF1 expression and promoted the platinum resistance phenotype [106].